Analysts Offer Insights on Healthcare Companies: Clene (CLNN), REPRO-MED Systems (KRMD) and Bioventus (BVS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Clene (CLNN – Research Report), REPRO-MED Systems (KRMD – Research Report) and Bioventus (BVS – Research Report) with bullish sentiments.

Clene (CLNN)

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Clene today and set a price target of $7.00. The company’s shares closed last Friday at $0.50.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 17.8% and a 47.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Bioline RX Ltd Sponsored ADR, and Actinium Pharmaceuticals.

Clene has an analyst consensus of Strong Buy, with a price target consensus of $7.00.

See today’s best-performing stocks on TipRanks >>

REPRO-MED Systems (KRMD)

In a report released today, Alexander Nowak from Craig-Hallum maintained a Buy rating on REPRO-MED Systems. The company’s shares closed last Friday at $2.21, close to its 52-week low of $1.98.

According to TipRanks.com, Nowak is a 3-star analyst with an average return of 1.6% and a 42.8% success rate. Nowak covers the Healthcare sector, focusing on stocks such as NeuroOne Medical Technologies, InfuSystem Holdings, Inc., and Phathom Pharmaceuticals.

Currently, the analyst consensus on REPRO-MED Systems is a Strong Buy with an average price target of $4.00, implying an 81.0% upside from current levels. In a report issued on March 6, Lake Street also maintained a Buy rating on the stock with a $4.00 price target.

Bioventus (BVS)

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Bioventus. The company’s shares closed last Friday at $5.40, close to its 52-week high of $5.74.

According to TipRanks.com, Knickerbocker is a 4-star analyst with an average return of 15.5% and a 66.1% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Avadel Pharmaceuticals, and Fennec Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bioventus.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CLNN:

• Clene Announces Breakthrough CNM-Au8 Treatment Results
• Clene presents clinical results of CNM-Au8 30mg treatment
• Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
• Clene’s CNM-Au8 Shows Promise in ALS Survival Rates
• Clene reports ‘significant’ survival results from two analyses of CNM-Au8